Plain-English translation of NCT06472245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new cancer vaccine called to see whether it works better than standard chemotherapy () for people with advanced lung cancer that has stopped responding to immunotherapy drugs. The vaccine is designed to train your immune system to fight cancer cells. You would receive either the new vaccine or the standard chemotherapy treatment, and researchers will compare how well each works and what side effects occur.
When immunotherapy drugs stop working against lung cancer, doctors usually turn to chemotherapy as the next option—but chemotherapy can be tough on the body and doesn't work for everyone. This trial exists to see if a personalized cancer vaccine might offer a gentler or more effective alternative for people in this situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new cancer vaccine or standard chemotherapy. The vaccine group receives small injections under the skin every three weeks for six cycles, then less frequently over the next two years. The chemotherapy group receives intravenous infusions every three weeks. You will have regular clinic visits to monitor your health, receive treatment, and have blood tests and scans to see how your cancer is responding.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States